My Account
Follow us on:
Powered By
See the top gainers, losers, invest and get updated what's happening in the crypto market
Invest Now
Discover the secret world of unlisted shares — analyse India's top pre-IPO companies and invest before they hit the markets
Mehraboon Irani of Nirmal Bang Securities remains negative on Ranbaxy. He says one should not buy the stock. "I don't see any reasons why Ranbaxy should be going up in a hurry at least from the present levels," he adds.
You are already a Moneycontrol Pro user.